Despite the late entry into the development of the Covid vaccine, Ocugen Inc (NASDAQ: OCGN) finds its place in the mid-cap space with revenues of $1.87 billion.  Investors can buy this stock at $9.70 before Ocugen submits EUA (Emergency Use Application) for its Covid vaccine – Covaxin to the US […]